Send Enquiry
CURE
Tablets
Packaging and packing Type
Blister | 10x10
MRP :
₹168
PTR :
₹120
PTS :
₹108
Belongs to a class of drugs called antianginal agents that are used in the treatment of chronic stable angina pectoris. (David T Nash, 2008) An antia... Read More
Composition
Send Enquiry
India’s Largest Pharma Franchise
100%
Genuine Products
Secure
Payments
24 x 7
Customer Support
About the product
Belongs to a class of drugs called antianginal agents that are used in the treatment of chronic stable angina pectoris. (David T Nash, 2008) An antianginal agent that relieves ischemia by reducing myocardial cellular sodium and calcium overload via inhibition of the late sodium current of the cardiac action potential. (Benjamin M Scirica, 2007) Offers clinicians a new option in the long-term treatment of patients with angina. (Benjamin M Scirica, 2007) A beneficial option for patients with chronic stable angina whose symptoms are not controlled with first-line antianginal therapy or who do not tolerate first-line antianginal agents. (Keating, 2008) A potent anti-anginal agent capable of producing anti-ischemic effects without reducing heart rate or blood pressure. (Charles Antzelevitch, 2004) A selective inhibitor of the late sodium current in myocytes with anti-ischemic and metabolic properties. (J Nicolás Codolosa, 2014) A cost-effective drug due to its ability to decrease angina-related hospitalizations and improve quality of life. (J Nicolás Codolosa, 2014) A promising therapeutic drug for patients who have chronic stable angina that failed conventional antianginal medications. (Bălan, 2010) Improves functional capacity and decreases anginal episodes in chronic stable angina patients. (J Nicolás Codolosa, 2014) A potent antianginal agent that, unlike beta-blockers, nitrates, or calcium channel blockers, does not affect either heart rate or blood pressure. (Wenger, 2010) Controls angina symptoms and improves exercise tolerance in patients with coronary heart disease. (Wenger, 2010) A good therapeutic choice for patients with chronic stable angina. (Andrea Rognoni, 2013) A valuable addition to the treatment of chronic stable angina with an excellent safety profile. (Ole Ahlehoff, 2009) Significantly reduces the frequency of anginal attacks and the need for use of short-acting nitroglycerine. (Thorsten Reffelmann, 2010) A safe and effective option for monotherapy or add-on therapy to reduce anginal symptoms in patients with chronic stable angina. (Robert A Kloner, 2013)
Dizziness, Headache, Nausea, Tiredness, Constipation
Chronic angina
Temp data
Storage Condition
Product details for storage condition Product details for storage condition Product details for storage condition Product details for storage condition
Similar Products
No products found.
Send Enquiry
Request a callback to get more information about becoming a PCD Franchise Owner